Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC
Sponsor: Zhejiang Provincial People's Hospital
Summary
The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
Official title: Clinical Exploratory Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of Anaplastic Thyroid Cancer (ATC)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-02-22
Completion Date
2029-03-01
Last Updated
2025-03-04
Healthy Volunteers
No
Conditions
Interventions
NKG2D CAR-NK with PD-1 Antibody
Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.
Locations (1)
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China